Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LENZ Stock 12 Month Forecast
Average Price Target
$48.67
▲(58.22%Upside)
| Highest Price Target$60.00 | Average Price Target$48.67 | Lowest Price Target$40.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Raymond James
$39→$40
Buy
30.04%
Upside
Reiterated
07/31/25
H.C. Wainwright
$48
Buy
56.05%
Upside
Reiterated
07/31/25
LENZ Therapeutics' LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market PositioningValuation and Risks. We reiterate our Buy rating and $48 price target. Our price target of $48 per share is based on an equally- weighted composite of: (a) $60.89 per share, as a 25x multiple of taxed and diluted 2034 EPS of $7.20 discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $35.17 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of a developmental- stage biopharmaceutical company.
Citi
$45→$49
Buy
59.30%
Upside
Reiterated
07/30/25
William Blair
―
Buy
―
Reiterated
07/30/25
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval1:44 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $31.67 Market Value (M): $891 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- 8 PDUFA What’s new? The FDA’s review of the LNZ100 NDA continues to progress with no delays or interruptions to date. The company completed its late-cycle review in May, and the FDA has noted no significant review issues. Lenz also continued to advance its commercial preparations during the second quarter, and has now completed hiring of its 88-member salesforce that is prepared to initiate sales-and-marketing activities immediately upon U.S. approval.
Bank of America Securities
$40→$44
Buy
43.04%
Upside
Reiterated
07/17/25
TD Cowen
$60
Buy
95.06%
Upside
Reiterated
06/13/25
Piper Sandler
$51
Buy
65.80%
Upside
Reiterated
05/08/25
Unknown AnalystTD Securities
Not Ranked
TD Securities
$60
Buy
95.06%
Upside
Initiated
03/18/25
Initiating At Buy: Ideal Eye Drop For Aging Eyes, In A Large Presbyopia Market We are initiating LENZ with a $60 target.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Raymond James
$39→$40
Buy
30.04%
Upside
Reiterated
07/31/25
H.C. Wainwright
$48
Buy
56.05%
Upside
Reiterated
07/31/25
LENZ Therapeutics' LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market PositioningValuation and Risks. We reiterate our Buy rating and $48 price target. Our price target of $48 per share is based on an equally- weighted composite of: (a) $60.89 per share, as a 25x multiple of taxed and diluted 2034 EPS of $7.20 discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $35.17 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of a developmental- stage biopharmaceutical company.
Citi
$45→$49
Buy
59.30%
Upside
Reiterated
07/30/25
William Blair
―
Buy
―
Reiterated
07/30/25
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval1:44 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $31.67 Market Value (M): $891 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- 8 PDUFA What’s new? The FDA’s review of the LNZ100 NDA continues to progress with no delays or interruptions to date. The company completed its late-cycle review in May, and the FDA has noted no significant review issues. Lenz also continued to advance its commercial preparations during the second quarter, and has now completed hiring of its 88-member salesforce that is prepared to initiate sales-and-marketing activities immediately upon U.S. approval.
Bank of America Securities
$40→$44
Buy
43.04%
Upside
Reiterated
07/17/25
TD Cowen
$60
Buy
95.06%
Upside
Reiterated
06/13/25
Piper Sandler
$51
Buy
65.80%
Upside
Reiterated
05/08/25
Unknown AnalystTD Securities
Not Ranked
TD Securities
$60
Buy
95.06%
Upside
Initiated
03/18/25
Initiating At Buy: Ideal Eye Drop For Aging Eyes, In A Large Presbyopia Market We are initiating LENZ with a $60 target.
Best Analysts Covering LENZ Therapeutics
1 Month
xxx
Success Rate
3/5 ratings generated profit
Average Return
+7.46%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +7.46% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+17.28%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +17.28% per trade.
1 Year
Success Rate
8/10 ratings generated profit
Average Return
+22.79%
reiterated a buy rating 21 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +22.79% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+27.24%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LENZ Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
5
9
11
9
7
Buy
8
7
10
6
8
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
17
22
16
15
Each month's total comprises the sum of three months' worth of ratings.
LENZ Financial Forecast
LENZ Stock Forecast FAQ
What is LENZ’s average 12-month price target, according to analysts?
Based on analyst ratings, LENZ Therapeutics’s 12-month average price target is 48.67.
What is LENZ’s upside potential, based on the analysts’ average price target?
LENZ Therapeutics has 58.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LENZ a Buy, Sell or Hold?
LENZ Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is LENZ Therapeutics’s price target?
The average price target for LENZ Therapeutics is 48.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $40.00. The average price target represents 58.22% Increase from the current price of $30.76.
The highest analyst price target is $60.00 ,the lowest forecast is $40.00. The average price target represents 58.22% Increase from the current price of $30.76.
What do analysts say about LENZ Therapeutics?
LENZ Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of LENZ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.